The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.
 
Kynan Feeney
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Ronan Kelly
Other Relationship - Bristol-Myers Squibb
 
Lara Rachel Lipton
Honoraria - Bayer
Consulting or Advisory Role - Amgen
 
Joseph Chao
Consulting or Advisory Role - AstraZeneca (Inst); Boston Biomedical; Five Prime Therapeutics; Lilly; Merck
Speakers' Bureau - Merck
Research Funding - Merck (Inst); Novonco Therapeutics (Inst)
 
Mirelis Acosta-Rivera
No Relationships to Disclose
 
Dennis Earle
No Relationships to Disclose
 
Ming Lei
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
Patents, Royalties, Other Intellectual Property - Columbia University
 
Georgia Kollia
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Niall C. Tebbutt
Honoraria - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer; Roche